The current therapeutic strategies for the management of patients with cirrhosis rely on the
prevention or treatment of specific complications. The removal of the causative agents (ie …

Background Despite antiviral therapy, liver function often fails to recover in patients with
hepatitis B virus (HBV)‐related decompensated cirrhosis. Aim To establish a prognostic …

Objectives Des-gamma-carboxyprothrombin (DCP) is an important serum biomarker for the
clinical screening of hepatocellular carcinoma (HCC). This study aimed to evaluate the …

Background and aims Disease progression could be altered or even reversed in
decompensated patients with HBV-related cirrhosis once they initiate antiviral therapy …

Abstract Background In sub-Saharan Africa, less than 1% of treatment-eligible chronic
hepatitis B (CHB) patients receive antiviral therapy. Experiences from local CHB programs …

肝硬化分期评价体系从关注疾病进展规律到进一步细化急性失代偿时疾病状态分类,
提出病因治疗后失代偿期肝硬化可再代偿的概念, 系统补充了失代偿期肝硬化分期评价体系 …

Background and objective Little is known about the influencing factors for recompensation in
HBV-related cirrhosis patients with ascites as the single first decompensating event and it's …

Cirrhosis has prognostic value. We investigated whether the combined use of
ultrasonography (US) and transient elastography (TE) to diagnose cirrhosis is beneficial for …

Abstract Background The Barcelona Clinic Liver Cancer (BCLC) categorizes a patient with
performance status (PS)-1 as advanced stage of hepatocellular carcinoma (HCC) and …

Clinical studies of tenofovir amibufenamide (TMF) and tenofovir alafenamide (TAF)
treatment in patients with HBV‐related decompensated cirrhosis (HBV‐DC) are limited. This …